Wockhardt is showing a strong bullish technical structure

WOCKPHARMA Wockhardt is showing a strong bullish technical structure as the stock is trading above all four important EMAs 21, 55, 100 and 200 EMA, indicating positive momentum across short-term, medium-term and long-term trends. When a stock sustains above these moving averages, it reflects buying interest and strengthening market sentiment, while these EMAs can act as dynamic support zones during corrections. Fundamentally, Wockhardt reported strong Q2 FY27 performance, with consolidated revenue increasing 24% YoY to ₹969 crore, while net profit stood at ₹73 crore. Its biotechnology business delivered impressive 68% growth, reaching ₹252 crore in quarterly revenue. Another major development is the expansion of its novel antibiotic portfolio: Zaynich has received US FDA approval and Indian regulatory approval, while Miqnaf has gained wider marketing access in India following the removal of a supply restriction. However, Q2 profit declined from ₹82 crore to ₹73 crore due to Zaynich launch-related expenses, which investors should monitor. Overall, the combination of bullish EMA alignment, biotechnology growth and progress in innovative antibiotics makes Wockhardt an interesting stock to track.